Market Overview

JMP Securities Covers Mostly Good News From Pharma Pending More Visibility


Achillion Pharmaceuticals Inc.'s (NASDAQ: ACHN) recent interim data for its developmental hepatitis C drug is "incrementally positive," according to JMP Securities' Liisa A. Bayko.

Achillion's Monday data dump is among a half-dozen drug company developments that JMP analysts commented on Tuesday.

Bayko reiterated an Outperform rating and $24 price target on Achillion, but called it a "high risk" clinical plan by the company to use its NS5A inhibitor, ACH-3102, in combination with Gilead Sciences Inc.'s (NASDAQ: GILD) Sovaldi treatment for hepatitis C.

Boston Scientific Corp. (NYSE: BSX) agreement to market C.R. Bard Inc.'s (NYSE: BCR) drug-coated balloon called Lutonix in the U.S. got a thumbs up from JMP's J.T. Haresco.

Hareso reiterated an Outperform rating and $17 target on Boston Scientific, and said the Bard agreement covers part of Boston's strategy for selling a complete array of products aimed at peripheral arterial disease.

Horizon Pharma PLC (NASDAQ: HZNP) is making good with its $45 million October acquisition of the osteoarthritis drug Pennsaid, with sales of the product tracking toward $40 million in annual sales, JMP's Oren G. Livnat said.

Livnat raised his target on Horizon 11 percent to $20 and maintained an Outperform rating on the company, citing a possible earnings surprise Feb. 29.

Organovo Holdings Inc. (NYSE: ONVO) released its first product, 3D human liver tissue in the third quarter, but on Monday posted related revenue of only $155,000 for the period.

Hareso reiterated a Market Perform rating and said he'll wait for more "visibility" on liver revenue.

Pharmacyclics Inc. (NASDAQ: PCYC) released promising data on its Imbruvica drug from a Phase I lymphoma trial. The drug received marketing clearance for a fourth related indication last month.

JMP's Michael King reiterated an Outperform rating on Pharmacyclics along with a $253 target, predicting 2015 sales of $1.4 billion.

Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH) may benefit from proposed legislation enabling it to transfer to another company one year of market exclusivity on its eravacycline antibiotic candidate.

The proposal, a small piece of the so-called 21st Century Cures bill now before Congress, could make Tetraphase a more attractive buyout candidate, "or alternatively, it could create a source of financing" once eravacycline is approved, according to Bayko.

Bayko maintained an Outperform rating and $58 target on Tetraphase Tuesday.

Latest Ratings for ACHN

May 2018BarclaysUpgradesUnderweightEqual-Weight
Feb 2018B. Riley FBRInitiates Coverage OnNeutral
Aug 2017BairdDowngradesOutperformNeutral

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: J.T. Haresco JMP Securities Michael King Oren G. LivnatAnalyst Color Analyst Ratings


Related Articles (ACHN + ACH)

View Comments and Join the Discussion!

Latest Ratings

VREXNorthland SecuritiesInitiates Coverage On42.0
EAMorgan StanleyMaintains88.0
ELMorgan StanleyMaintains178.0
SPLKMorgan StanleyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Stifel Nicolaus Upgrades Dun & Bradstreet To Buy

Reynolds American Inc. Q4 Shipments Fall 5%, Vs 1.7% For Altria Group Inc.